These treatments have shown great promise, and immune checkpoint inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway in particular, have now been approved as first- or second-line treatments for melanoma, lymphoma, and other malignancies [3]. This evidence concerns the gene PDCD1 and lymphoma.